In most cases, yesreflux symptoms typically resolve within days to weeks after stopping GLP-1 medication
Diabetes Care 40(12):17901799
In this phase 3b open-label, randomised, controlled trial, 751 adult participants with obesity, but without type 2 diabetes, in a 1:1 ratio received tirzepatide maximum tolerated dose (10mg or 15mg) or semaglutide maximum tolerated dose (1.7mg or 2.4mg) subcutaneously once weekly for 72 weeks
Policymakers should drive more equitable access of GLP-1 treatments as the benefits become more significant and proactively update guidelines for preventative use to ensure broader eligibility and earlier intervention
Reddy's", The Globe and Mail , archived from the original on 29 April 2026 1 2 3 4 "Brazil approves first generic semaglutide pen after Ozempic patent expiry", Reuters website "Brazilian federal court denies semaglutide patent extension"